STOCK TITAN

Immuneering to Present at the Jefferies Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, announced its participation in the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City from June 5-6, 2024. The company's management team, including CEO Ben Zeskind and Chief Accounting Officer Mallory Morales, will discuss their pipeline, platform, and business strategy. The presentation is scheduled for June 5 from 4:30 – 4:55 pm ET in Track 2 and will be webcast live. The webcast will be archived in the Investor Relations section of Immuneering's website.

Positive
  • Immuneering's participation in a prestigious healthcare conference boosts visibility.
  • Presentation by high-level executives (CEO and Chief Accounting Officer) indicates strategic importance.
  • Webcast availability increases accessibility for a broader audience, including potential investors.
Negative
  • The announcement lacks specific new data or significant updates that could drive immediate stock movement.
  • No mention of financial performance or clinical trial results, leaving critical investor questions unanswered.

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 5-6, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Co-founder and Chief Executive Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

Format: Company Presentation and 1x1 Investor Meetings

Presentation: June 5 from 4:30 – 4:55 pm ET in Track 2

The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The Company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.

Media Contact:
Gina Nugent
gina@nugentcommunications.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com


FAQ

When will Immuneering present at the Jefferies Global Healthcare Conference?

Immuneering will present on June 5, 2024, from 4:30 – 4:55 pm ET in Track 2.

Where is the Jefferies Global Healthcare Conference taking place?

The Jefferies Global Healthcare Conference is taking place at the Marriott Marquis in New York City.

Who from Immuneering will participate in the presentation?

CEO Ben Zeskind and Chief Accounting Officer Mallory Morales will participate in the presentation.

Will the Immuneering presentation be available online?

Yes, the presentation will be webcast live and archived on Immuneering's website in the Investor Relations section.

What is the stock symbol for Immuneering ?

The stock symbol for Immuneering is IMRX.

Immuneering Corporation

NASDAQ:IMRX

IMRX Rankings

IMRX Latest News

IMRX Stock Data

57.76M
22.40M
29.12%
30.11%
6.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE